BWX Technologies (BWXT) Earnings Date & Reports

Key Takeaways

• BWXT reported Q2 2026 revenue of $901.6 million, up 18% year-over-year, coming in slightly below the consensus estimate of approximately $905.4 million.
• Non-GAAP earnings per share (EPS) of $1.07 beat analyst expectations of $1.05, while GAAP EPS reached $0.97, compared to $0.85 in the prior-year period.
• Commercial Operations revenue surged 72% to $302.5 million, fueled by broad-based strength across nuclear components, field services, fuel handling, and the Kinectrics acquisition.
• The company raised full-year 2026 guidance across all key metrics, including revenue (~$3.80 billion), adjusted EBITDA ($662–$672 million), non-GAAP EPS ($4.70–$4.80), and free cash flow ($345–$360 million).
• Total backlog climbed to $8.4 billion, a 40% year-over-year increase, supported by robust bookings and a $1.4 billion Naval Nuclear Propulsion Program contract award.
• BWXT announced the sale of its medical business and closed the Precision Components Group (PCG) acquisition, sharpening its focus on nuclear national security and commercial power markets.

Earnings Context and Why It Matters

BWX Technologies' second-quarter 2026 results arrive at a pivotal moment for the nuclear industry. With global investment in nuclear energy accelerating — driven by decarbonization goals, energy security concerns, and expanding defense budgets — BWXT sits at the intersection of two powerful demand trends. The company's Government Operations segment supplies naval nuclear reactors for U.S. submarines and aircraft carriers, while its Commercial Operations segment serves the growing market for nuclear power components and services. Coming off a strong Q1 2026 in which non-GAAP EPS of $1.12 beat estimates by $0.20, this quarter's report was closely watched for signs of sustained momentum, particularly in commercial nuclear markets, and for progress on the company's strategic repositioning following the PCG acquisition and the medical business divestiture.

Reported Results

BWX Technologies reported second-quarter 2026 consolidated revenue of $901.6 million, an 18% increase from $764.0 million in the same quarter last year. The result narrowly missed Wall Street's consensus estimate of roughly $905.4 million. Organic revenue growth, excluding acquisitions, was approximately 9%.

On the bottom line, GAAP net income rose to $89.1 million, or $0.97 per diluted share, compared to $78.5 million, or $0.85 per share, in Q2 2025. Non-GAAP EPS, which excludes restructuring charges, acquisition-related costs, and acquisition-related amortization, came in at $1.07, exceeding the analyst consensus of $1.05 and up from $1.02 a year earlier. Consolidated adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) increased 7% to $155.5 million.

Segment performance revealed a striking divergence. Government Operations generated $601.3 million in revenue, a modest 2% increase driven by naval propulsion and special materials programs, partially offset by lower advanced nuclear volumes. Segment adjusted EBITDA declined 5% to $126.5 million, with margins compressing to 21.0% from 22.6%, reflecting less favorable contract adjustments compared to the prior-year period. In contrast, Commercial Operations revenue soared 72% to $302.5 million, including 33% organic growth. Adjusted EBITDA more than doubled to $36.1 million, with margins expanding to 11.9% from 9.2%.

Free cash flow for the quarter totaled $115.0 million, down from $126.3 million a year ago, as higher capital expenditures of $41.4 million — primarily tied to growth projects in Commercial Operations — partially offset strong operating cash flow of $156.4 million. The company also declared a quarterly dividend of $0.27 per share.

AI Screener

For investors seeking to identify opportunities across the nuclear energy, defense, and industrial sectors, Tickeron's AI Screener offers a data-driven solution. This AI-powered stock and ETF discovery tool enables traders and investors to filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-generated signals. By scanning for breakout candidates, trending stocks, and emerging trade ideas in real time, the screener helps users cut through market noise more efficiently than manual research alone. Whether tracking defense contractors like BWXT or surveying the broader nuclear supply chain, the AI Screener provides a streamlined way to surface actionable investment ideas grounded in quantitative analysis.

Market Reaction and Investor Sentiment

Despite delivering an earnings beat and raising full-year guidance, BWXT shares experienced a mixed reaction. The stock closed the regular trading session on August 3 up 3.02% at $173.79, but subsequently fell 3.23% to $168.18 in after-hours trading following the earnings release. The after-hours decline suggests that investors focused on the slight top-line miss against consensus estimates and higher planned capital spending rather than the company's improved full-year outlook. Additionally, the margin compression in Government Operations — the company's largest and historically most stable segment — may have given some investors pause, even as Commercial Operations demonstrated accelerating profitability. Heading into the report, sentiment had been broadly positive, buoyed by the $1.4 billion naval contract announcement and growing enthusiasm around nuclear energy as a long-term structural growth theme.

Forward Outlook and Key Factors to Monitor

BWXT enters the second half of 2026 with considerable momentum, underscored by a raised guidance range that now calls for approximately $3.80 billion in full-year revenue, adjusted EBITDA of $662 million to $672 million, and non-GAAP EPS of $4.70 to $4.80. These upgraded targets incorporate the contribution from the PCG acquisition, which closed on July 1, 2026, and establish a U.S.-based commercial nuclear component manufacturing footprint for the company.

Several factors will shape the investment narrative through year-end. First, the integration of PCG and the ramp-up of U.S. commercial manufacturing capacity represent both an operational opportunity and an execution risk. Second, the announced sale of the medical business signals a sharper strategic focus on nuclear national security and commercial power — investors will be monitoring how effectively management reallocates resources toward these core markets.

On the demand side, BWXT's backlog of $8.4 billion provides strong revenue visibility, but converting this backlog into profitable growth will depend on sustained operational execution and disciplined cost management. The Government Operations segment faces margin headwinds from business mix shifts and tougher year-over-year comparisons on contract adjustments. Meanwhile, Commercial Operations must demonstrate that its rapid growth trajectory and margin expansion are sustainable beyond the near-term surge driven by acquisitions and catch-up demand.

Broader industry dynamics also warrant attention. The accelerating global push for nuclear energy — spanning small modular reactors (SMRs), advanced fuels such as TRISO (tristructural isotropic particle fuel) and HALEU (high-assay low-enriched uranium), and naval fleet modernization — creates a favorable multi-year backdrop. However, capital spending requirements, supply chain constraints, and the pace of regulatory approvals will influence how quickly BWXT can capitalize on these tailwinds. Investors should also watch for further contract awards under the Naval Nuclear Propulsion Program, where the company's five-year task order structure provides a steady pipeline of opportunities through 2030.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations